ACTIVATION OF BCR-ABL FUSION GENE AND RAS ONCOGENES IN CHRONIC MYELOGENOUS LEUKEMIA

被引:4
|
作者
FUTAKI, M
INOKUCHI, K
DAN, K
NOMURA, T
机构
[1] The Third Department of Internal Medicine, Nippon Medical School, Tokyo
关键词
CML; PHILADELPHIA CHROMOSOME; BCR-ABL FUSION GENE; TRANSFORMING; GENE; RAS ONCOGENES;
D O I
10.3109/10428199109068121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We attempted to detect the bcr-abl fusion gene and ras gene family in CML by the in vitro focus forming assay and the tumorigenicity assay. Eight of 14 chronic phase and both of two blastic phase cases showed transforming activity in the tumorigenicity assay. However, only one chronic phase sample was positive in the in vitro focus forming assay. Among these 10 transformants, we found N-ras activation in one chronic phase, and K-ras activation in another chronic phase case. The bcr-abl fusion gene was activated in one chronic phase and all of the blastic phase cases by the tumorigenicity assay. The present result showed that the bcr-abl fusion gene transfected N1H3T3 cells formed tumors in nude mice in contrast to the in vitro focus forming assay. The bcr-abl fusion gene may play important roles in the progression as well as the pathogenesis of CML. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [31] BCR-ABL FUSION GENES IN HUMAN CHRONIC MYELOGENEOUS LEUKEMIA
    BOEHM, TLJ
    HIRTH, HP
    WERLE, A
    DRAHOVSKY, D
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1985, 366 (09): : 767 - 767
  • [32] Qualitative and Quantitative Evaluation of the BCR-ABL Fusion Gene in Chronic Myelogenous Leukemia by Flourescence In Situ Hybridization and Molecular Genetic Methods
    Sag, Sebnem Ozemri
    Yakut, Tahsin
    Gorukmez, Ozlem
    Gorukmez, Orhan
    Ture, Mehmet
    Karkucak, Mutlu
    Gulten, Tuna
    Ali, Ridvan
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2015, 19 (10) : 584 - 588
  • [33] Vaccination of patients with chronic myelogenous leukemia using leukemia-specific bcr-abl breakpoint fusion peptides.
    Scheinberg, DA
    Bocchia, M
    Koronstvit, T
    Caggiano, J
    Weiss, M
    Kolitz, J
    Megherian, L
    George, D
    BLOOD, 1996, 88 (10) : 3534 - 3534
  • [34] Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
    Hai, Abdul
    Kizilbash, Nadeem A.
    Zaidi, Syeda Huma H.
    Alruwaili, Jamal
    Shahzad, Khuram
    BIOINFORMATION, 2014, 10 (03) : 108 - 114
  • [35] BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer, Katharina M.
    Werth, Daniela
    von Schwarzenberg, Karin
    Bringmann, Anita
    Kanz, Lothar
    Gruenebach, Frank
    Brossart, Peter
    BLOOD, 2006, 108 (11) : 624A - 625A
  • [36] Exploring the contribution of ubiquitin binding domain of Bcr-Abl in chronic myelogenous leukemia
    Chen, Ru
    Mahon, Gwen
    Tala, Ilona
    Chen, Qing
    Hu, Tinghui
    Li, Dan
    Ozer, Harvey
    Whitehead, Ian
    CANCER RESEARCH, 2012, 72
  • [37] Prognostic significance of the type of BCR-ABL transcript in chronic myelogenous leukemia (CML)
    Mantzourani, M
    Viniou, N
    Stavroyianni, N
    Rombos, J
    Meletis, J
    Loukopoulos, D
    Yataganas, X
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 275 - 275
  • [38] Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia
    Narita, Miwako
    Saito, Anri
    Kojima, Aya
    Iwabuchi, Minami
    Satoh, Naoya
    Uchiyama, Takayoshi
    Yamahira, Akie
    Furukawa, Tatsuo
    Sone, Hirohito
    Takahashi, Masuhiro
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2012, 9 (10): : 901 - 908
  • [39] Employing DNAzymes to target bcr-abl mRNA in chronic myelogenous leukemia.
    Joyce, GF
    BLOOD CELLS MOLECULES AND DISEASES, 2000, 26 (01) : 60 - 61
  • [40] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677